Senti Biosciences Board Changes and Officer Compensation

Ticker: SNTI · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1854270

Sentiment: neutral

Topics: board-change, officer-compensation

TL;DR

Senti Bio board shakeup: Dr. Pesce out, Dr. Drachman in. Officer comp details also filed.

AI Summary

Senti Biosciences, Inc. announced on March 6, 2025, a change in its board of directors, with the departure of Dr. Philip P. Pesce and the appointment of Dr. Jonathan G. Drachman. The company also disclosed compensatory arrangements for certain officers and other events, with the filing dated March 10, 2025.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes and executive compensation disclosures can indicate internal shifts that may affect the company's direction and stability.

Key Players & Entities

FAQ

Who departed from the Senti Biosciences board of directors?

Dr. Philip P. Pesce departed from the Senti Biosciences board of directors.

Who was appointed to the Senti Biosciences board of directors?

Dr. Jonathan G. Drachman was appointed to the Senti Biosciences board of directors.

What is the earliest event date reported in this 8-K filing?

The earliest event date reported is March 6, 2025.

What is the filing date of this 8-K report?

The filing date of this 8-K report is March 10, 2025.

What other items are disclosed in this 8-K filing besides director changes?

This 8-K filing also discloses compensatory arrangements of certain officers and other events.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 by Dr. Philip P. Pesce regarding Senti Biosciences, Inc. (SNTI).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing